• Douglas J Weschules, Terri L Maxwell, and Joseph W Shega.
• GlaxoSmithKline, Philadelphia, Pennsylvania 19101, USA. douglas.j.weschules@gsk.com
• J Palliat Med. 2008 Jun 1;11(5):738-45.

ObjectivesTo describe acetylcholinesterase inhibitor (AChEI) and memantine use among persons over the age of 65 admitted to hospice with a primary diagnosis of dementia and identify patient and hospice program characteristics associated with the use of these agents.DesignRetrospective, cross-sectional study.SettingAdministrative database of a national hospice pharmacy provider.ParticipantsA total of 10,065 persons with end-stage dementia admitted to one of 441 U.S. hospices in 2004.MeasurementsThe frequency of AChEI and memantine use was determined and utilized as the unit of analysis for bivariate and multivariate comparisons with patient and hospice program characteristics.ResultsTwenty-one percent (2148/10,065) of patients were prescribed AChEI and/or memantine therapy at the time of hospice enrollment. Of these, 49.5% were prescribed donepezil. Odds of receiving AChEI and/or memantine therapy were less likely if the patient was female, (odds ratio [OR] 0.68, 0.62-0.76), died while enrolled in hospice (OR 0.75, 0.67-0.85), received care at home (0.80, 0.71-0.89), or had a hospice length of stay (LOS) less than 7 days (0.53, 0.45-0.62). Patients who had a LOS of at least 60 days were significantly more likely to have received such therapies (OR 1.41 [1.24-1.60] for 61-180 days and 1.33 [1.15-1.54] for over 180 days).ConclusionA notable number of hospice enrollees with a primary diagnosis of dementia were prescribed AChEI and/or NMDA receptor antagonist therapy. Studies are needed to better define the role of these agents as well as the impact of medication discontinuation in persons with end-stage dementia.

17 keywords...

hide…